<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811435917</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811435917</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical and Polygraphic Improvement of Breathing Abnormalities After Valproate in a Case of Pitt-Hopkins Syndrome </article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Maini</surname>
<given-names>Ilenia</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435917">1</xref>
<xref ref-type="aff" rid="aff3-0883073811435917">*</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cantalupo</surname>
<given-names>Gaetano</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435917">1</xref>
<xref ref-type="aff" rid="aff3-0883073811435917">*</xref>
<xref ref-type="corresp" rid="corresp1-0883073811435917"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turco</surname>
<given-names>Emanuela Claudia</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435917">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paolis</surname>
<given-names>Fernando De</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811435917">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Magnani</surname>
<given-names>Cinzia</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435917">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parrino</surname>
<given-names>Liborio</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-0883073811435917">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Terzano</surname>
<given-names>Mario Giovanni</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811435917">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pisani</surname>
<given-names>Francesco</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435917">1</xref>
</contrib>
</contrib-group>
<aff id="aff3-0883073811435917">
<label>*</label>Authors contributed equally to this work </aff>
<aff id="aff1-0883073811435917">
<label>1</label>Child Neuropsychiatry Unit, University of Parma, Parma, Italy</aff>
<aff id="aff2-0883073811435917">
<label>2</label>Sleep Disorders Center, Department of Neurosciences, University of Parma, Italy</aff>
<author-notes>
<corresp id="corresp1-0883073811435917">Gaetano Cantalupo, MD, Child Neuropsychiatry Unit, Via Gramsci, 14 Azienda Ospedaliero-Universitaria di Parma, 43100 Parma, Italy Email: <email>gcantalupo@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>12</issue>
<fpage>1585</fpage>
<lpage>1588</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Pitt-Hopkins syndrome is a rare genetic form of severe psychomotor delay, caused by mutations in transcription cell factor-4 gene and characterized by distinctive dysmorphic features and abnormal breathing pattern. The current report describes the polygraphic features of the syndrome’s typical breathing pattern in a patient both in wakefulness and in sleep. The control of these breathing alterations is important to prevent the neurological sequelae linked to chronic cerebral hypoxemia in early ages. No data are available on effective treatment options for breathing abnormalities of Pitt-Hopkins syndrome. The authors polygraphically documented a reduction of apneic and hypopneic phenomena, with a significant improvement in saturation values, after the introduction of sodium valproate.</p>
</abstract>
<kwd-group>
<kwd>clinical neurophysiology</kwd>
<kwd>central apneas</kwd>
<kwd>mental retardation</kwd>
<kwd>valproate</kwd>
<kwd>Pitt- Hopkins</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Pitt-Hopkins syndrome is a rare cause of severe psychomotor delay, characterized by a distinctive phenotype and a particular breathing pattern, which appears during early childhood or adolescence, solely during wakefulness, as paroxysms of tachypnea episodes (sometimes followed by apnea and cyanosis).<sup><xref ref-type="bibr" rid="bibr1-0883073811435917">1</xref></sup> About 50 cases have been reported.</p>
<p>In 2007, the haploinsufficiency of transcription cell factor-4, due to an autosomal dominant de novo mutation, was identified to be causative of Pitt-Hopkins syndrome.<sup><xref ref-type="bibr" rid="bibr2-0883073811435917">2</xref></sup>
</p>
<p>Here we describe a patient affected by Pitt-Hopkins syndrome with regard to the polygraphic characterization of the syndrome’s typical breathing pattern in wakefulness and sleep and to the changes induced by a specific drug therapy.</p>
<sec id="section1-0883073811435917">
<title>Case Summary</title>
<p>The child was 7 years old when she was referred to our unit for the onset of breathing paroxysms during wakefulness. The respiratory events were characterized by intermittent hyperpnea alternating with episodes of apnea, sometimes associated with cyanosis.</p>
<p>Clinical observation revealed severe mental retardation, lack of language, wide-base gait, and mild dysmorphic features such as microcephaly, macrostomia, and “Cupid’s bow”–shaped upper lip. The initial suspicion of Pitt-Hopkins syndrome was confirmed by the heterozygous mutation of transcription cell factor-4 gene (p.Val184MetfsX15). Routine electroencephalography (EEG) ruled out the presence of epileptic discharges associated with apneic–hyperpneic events. To characterize the child’s respiratory pattern, we recorded a dynamic 24-hour polysomnography.</p>
<p>During wakefulness, the polysomnography recording showed the occurrence of central apneic and hypopneic events with central apnea/hypopnea index of 22.8/h. Apnea episodes showed a mean duration of 42 seconds and were almost invariably associated with severe oxygen desaturation. Index of desaturation was 16.8/h. The 43% of the waking time was spent at arterial oxygen saturation less that 90%, with lowest value of saturation of 50% and average value of 86%. Apneic events alternated with periods of hyperpnea and/or increase of inspired volume (<xref ref-type="fig" rid="fig1-0883073811435917">Figure 1</xref>).</p>
<fig id="fig1-0883073811435917" position="float">
<label>Figure 1.</label>
<caption>
<p>Respiratory pattern during wakefulness and sleep before treatment. In both A and B, upper line shows the wake–sleep histogram (S1, stage 1; S2, stage 2; S3, stage 3; S4, stage 4; REM, rapid eye movement sleep) before the introduction of sodium valproate, whereas below is depicted a 7-minute window of polygraphic recording, corresponding to the blue-shaded interval on the wake–sleep histogram. The first 4 traces are the electroencephalography (EEG) channels (F4-C4, C4-P4, P4-O2, and C4-A1), and the subsequent traces are, from top to bottom, snoring noise, nasal flow, thoracic movements, and oxygen saturation. (A) During wakefulness, the abnormal breathing pattern was characterized by recurrence of tachypnea and/or increase of inspired volume (dotted boxes) alternated with long central apneas (closed boxes), in the absence of airway obstruction and snoring. The hyperpneic periods are followed by transient slowing of EEG activity, whereas central apneas determine severe oxygen desaturations. When analyzed at a slower time line, the EEG tracing does not show evidence of epileptic discharges or electrodecremental responses preceding or associated with the onset of apneic events. The apparent persistence of thoracic movements during central apneas is an artifact due to the subcontinuous movements of trunk and limbs. (B) During non–rapid eye movement (NREM) sleep, regular respiration and stable oxygen saturation are evident.</p>
</caption>
<graphic xlink:href="10.1177_0883073811435917-fig1.tif"/>
</fig>
<p>During sleep (<xref ref-type="fig" rid="fig1-0883073811435917">Figure 1</xref>), we observed a physiological organization of sleep structure (Rechtschaffen &amp; Kales scoring) with regular breathing both in rapid eye movement (REM) and non–rapid eye movement (NREM) stages and only occasional central respiratory events of short duration, associated with EEG arousal but with no effects on oxygen saturation (apnea/hypopnea index 0.9/h; index of desaturation 0/h; and mean saturation 98.6%).</p>
<p>Introduction of diazepam at the dose of 0.25 mg/kg/d induced no clinical improvement but excessive sleepiness. We started a gradual titration of sodium valproate, obtaining clinical improvement at the dose of 25 mg/kg/d, reaching a blood level of 105 ng/mL.</p>
<p>Seven months after the introduction of sodium valproate, polysomnography recording showed the persistence of a subcontinuous abnormal breathing pattern during wakefulness characterized by periods of hyperpnea and overlapping movement artifacts. However, apneic or hypopneic phenomena were sporadic (apnea/hypopnea index 5/h), with a significant improvement in saturation values. Only 1% of waking time was spent at arterial oxygen saturation less than 90%, with lowest value of desaturation of 84% and mean saturation of 99%. Index of desaturation was 4/h (<xref ref-type="fig" rid="fig2-0883073811435917">Figure 2</xref>).</p>
<fig id="fig2-0883073811435917" position="float">
<label>Figure 2.</label>
<caption>
<p>Cardiorespiratory polygraphic recording (without electroencephalography [EEG] channels) during wakefulness performed 7 months after introduction of sodium valproate therapy (5-minute window). From top to bottom: nasal flow, thoracic and abdominal movements, oxygen saturation, and heart rate. Note the persistence of a chaotic breathing during wakefulness but without central apneas and notably no oxygen desaturations.</p>
</caption>
<graphic xlink:href="10.1177_0883073811435917-fig2.tif"/>
</fig>
</sec>
<sec id="section2-0883073811435917">
<title>Discussion</title>
<p>Although the overall clinical course of our patient is very typical in Pitt-Hopkins syndrome, and childhood-onset breathing abnormalities alternating hyperpnea and apneas have been described in more than half of genetically confirmed Pitt-Hopkins syndrome cases,<sup><xref ref-type="bibr" rid="bibr1-0883073811435917">1</xref>,<xref ref-type="bibr" rid="bibr3-0883073811435917">3</xref></sup> to our knowledge this is the first polygraphic documentation of the phenomenon. Moreover, our report objectively measured an improvement in respiratory pattern in a patient with Pitt-Hopkins syndrome treated with sodium valproate.</p>
<p>The control of these breathing alterations is important to prevent the neurological sequelae linked to chronic cerebral hypoxemia in early ages, but so far treatment attempts have been reported exclusively for Rett syndrome,<sup><xref ref-type="bibr" rid="bibr4-0883073811435917">4</xref></sup> whereas studies on drug treatment in Pitt-Hopkins syndrome focused only on epileptic seizure management.</p>
<p>In Pitt-Hopkins syndrome the defective interaction of transcription cell factor-4 with the ASCL1-PHOX-RET pathway could alter the development of the noradrenergic system neurons involved in the respiratory rhythm generator modulation and maturation.<sup><xref ref-type="bibr" rid="bibr2-0883073811435917">2</xref></sup> Therefore, as well as in Rett syndrome,<sup><xref ref-type="bibr" rid="bibr5-0883073811435917">5</xref></sup> the abnormal respiratory pattern could be related to an anomalous maturation of the inhibitory activity in the neuronal networks involved in the breathing rhythmogenesis. The causal role of a delayed differentiation of brainstem neural circuitry is also supported by studies on animal models, in which it has been demonstrated that the transcription cell factor-4 defect can impair the migration of neural progenitors, reducing the number of differentiated neurons in pontine nucleus.<sup><xref ref-type="bibr" rid="bibr3-0883073811435917">3</xref>,<xref ref-type="bibr" rid="bibr6-0883073811435917">6</xref></sup>
</p>
<p>We hypothesized that any possible improvement of breathing abnormalities could be modulated by a γ-aminobutyric acid (GABA)-mediated synaptic action that is critical to network synchronization for breathing control.<sup><xref ref-type="bibr" rid="bibr7-0883073811435917">7</xref></sup> In particular, we expected that a drug-mediated attenuation of hyperpnea episodes, typical of the onset of Pitt-Hopkins syndrome’s breathing pattern, could attenuate the apneic episodes and consequent hypoxemia.<sup><xref ref-type="bibr" rid="bibr8-0883073811435917">8</xref></sup>
</p>
<p>After our first unsuccessful attempt of therapy with diazepam we tried to exploit the GABAergic action of sodium valproate. The improvement achieved may be due either to the direct action of sodium valproate on GABA’s metabolism, different from that of diazepam on GABA<sub>A</sub> receptor, or to the related actions of sodium valproate that attenuates <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA)-mediated excitation and blocks Na<sup>+</sup> channels, Ca<sup>2+</sup> channels, and voltage-gated K<sup>+</sup> channels.<sup><xref ref-type="bibr" rid="bibr9-0883073811435917">9</xref></sup> Several studies reported the involvement of NMDA, Na<sup>+</sup> channels, Ca<sup>2+</sup> channels, and voltage-gated K<sup>+</sup> channels on the respiratory rhythm generation within the pre-Bötzinger complex.<sup><xref ref-type="bibr" rid="bibr10-0883073811435917">10</xref></sup> Sodium valproate efficacy is also possibly related to its inhibitory activity on histone deacetylases, which in turn is thought to produce epigenetic effects such as enhancing the expression of cyclin D2 as well as of survival genes, leading to increased numbers of GABAergic neurons, neurite outgrowth, and neuronal differentiation.<sup><xref ref-type="bibr" rid="bibr11-0883073811435917">11</xref></sup> Moreover, histone deacetylase inhibition upregulates neuron-specific genes through the neuron-located basic helix–loop–helix transcription factor, NeuroD,<sup><xref ref-type="bibr" rid="bibr11-0883073811435917">11</xref></sup> which is expressed in the adult brain in a circadian fashion, whose kinetic profile is interestingly influenced by transcription cell factor-4,<sup><xref ref-type="bibr" rid="bibr12-0883073811435917">12</xref></sup> suggesting a link to explain the circadian or state-dependent modulation of the breathing alterations observed in Pitt-Hopkins syndrome.</p>
<p>The present investigation can be considered as a starting point for more extensive studies on the treatment of respiratory abnormalities in Pitt-Hopkins syndrome.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Nicoletta Azzi, Valentina Rosso, and Rosalia Geraci for their invaluable technical support. We also thank Professor Oliviero Bruni for his help in revising the manuscript and the anonymous reviewers for useful suggestions.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1a-0883073811435917"><label>Author Contributions</label>
<p>I. Maini wrote the initial draft under the other authors’ supervision. E.C. Turco and G. Cantalupo collected and organized clinical data. G. Cantalupo and F. De Paolis analyzed and interpreted neurophysiological data and revised the manuscript. C. Magnani performed the genetic diagnosis and revised the manuscript. L. Parrino and M.G. Terzano contributed to polysomnographic analysis and revised the manuscript. F. Pisani provided suggestions for the interpretation of both clinical and neurophysiological data and accomplished the final version of this paper. Maini and Cantalupo are the first authors who contributed equally to this work.</p></fn>
<fn fn-type="conflict" id="fn1-0883073811435917"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073811435917"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn2a-0883073811435917"><label>Ethical Approval</label>
<p>The patient’s parents were informed and gave their consent to publish all clinical information.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811435917">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taddeucci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bonucelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mantellassi</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>Pitt-Hopkins syndrome: report of a case with a TCF4 gene mutation</article-title>. <source>Ital J Pediatr</source>. <year>2010</year>;<volume>36</volume>:<fpage>12</fpage>.</citation>
</ref>
<ref id="bibr2-0883073811435917">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zweier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peippo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Hoyer</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Haploinsufficiency of TCF4 causes syndromal mental retardation with intermittent hyperventilation (Pitt-Hopkins syndrome)</article-title>. <source>Am J Hum Genet</source>. <year>2007</year>;<volume>80</volume>(<issue>5</issue>):<fpage>994</fpage>–<lpage>1001</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811435917">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brockschmidt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Filippi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Charbel Issa</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Neurologic and ocular phenotype in Pitt-Hopkins syndrome and a zebrafish model</article-title>. <source>Hum Genet</source>. <year>2011</year>;<volume>130</volume>:<fpage>645</fpage>–<lpage>655</lpage>.</citation>
</ref>
<ref id="bibr4-0883073811435917">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Dutschmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ramirez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hilaire</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Breathing disorders in Rett syndrome: progressive neurochemical dysfunction in the respiratory network after birth</article-title>. <source>Respir Physiol Neurobiol</source>. <year>2009</year>;<volume>168</volume>:<fpage>101</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811435917">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alison</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Julu</surname>
<given-names>PO</given-names>
</name>
</person-group>. <article-title>Recent insight into hyperventilation from the study of Rett syndrome</article-title>. <source>Arch Dis Child</source>. <year>1999</year>;<volume>80</volume>:<fpage>384</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr6-0883073811435917">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flora</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Thaller</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zoghbi</surname>
<given-names>HY</given-names>
</name>
</person-group>. <article-title>The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>:<fpage>15382</fpage>–<lpage>15387</lpage>.</citation>
</ref>
<ref id="bibr8-0883073811435917">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bou-Flores</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Gap junctions and inhibitory synapses modulate inspiratory motoneuron synchronization</article-title>. <source>J Neurophysiol</source>. <year>2001</year>;<volume>85</volume>:<fpage>1543</fpage>–<lpage>1551</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811435917">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Southall</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Tirosh</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Hyperventilation in the awake state: potentially treatable component of Rett Syndrome</article-title>. <source>Arch Dis Child</source>. <year>1988</year>;<volume>63</volume>:<fpage>1039</fpage>–<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr9-0883073811435917">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chateauvieux</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Morceau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dicato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Diedrich</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Molecular and therapeutic potential and toxicity of valproic acid</article-title>. <source>J Biomed Biotechnol</source>. <year>2010</year>;<comment>2010. article ID 479364</comment>.</citation>
</ref>
<ref id="bibr10-0883073811435917">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ballanyi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Onimar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Homma</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Respiratory network function in the isolated brainstem-spinal cord of newborn rats</article-title>. <source>Prog Neurobiol</source>. <year>1999</year>;<volume>59</volume>:<fpage>583</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr11-0883073811435917">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Polazzi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Contestabile</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection</article-title>. <source>Curr Mol Pharmacol</source>. <year>2009</year>;<volume>2</volume>:<fpage>95</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr12-0883073811435917">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brzózka</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Radyushkin</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wichert</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Ehrenreich</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rossner</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain</article-title>. <source>Biol Psychiatry</source>. <year>2010</year>;<volume>68</volume>:<fpage>33</fpage>–<lpage>40</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>